Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr approved to sell generic antidiuretic drug in US
Barr Laboratories, a subsidiary of Barr Pharmaceuticals, is the first company to file an application to the FDA for a generic version of DDAVP (desmopressin acetate) 0.1mg and
Barr Laboratories, a subsidiary of Barr Pharmaceuticals, is the first company to file an application to the FDA for a generic version of DDAVP (desmopressin acetate) 0.1mg and
Researchers screened 150 peptides for activity against cystic fibrosis (CF) pathogens in the presence of factors that mimic the physiological environment of the CF lung. Peptides with good
The placebo controlled phase II trial to be conducted in a single center in Europe is investigating the efficacy and safety of growth hormone releasing hormone (GHRH). A
The study will be conducted using the company’s advanced intranasal formulation that utilizes its ‘Tight Junction’ drug delivery technology to enable needle-free delivery of therapeutic levels of drugs,
Brisbane, California-based Stentor develops picture archiving and communication systems (PACS) used for storing, managing and distributing digital radiology images throughout hospitals and healthcare facilities. As part of the
The clinical trial is being conducted in patients with the neovascular or “wet” form of age related macular degeneration (wet AMD), a degenerative condition that is a major
A total of 32 patients with recurring non-small cell lung cancer (NSCLC) received 10 mg/kg doses of Human Genome’s mapatumumab treatment, HGS-ETR1, administered as an intravenous infusion 21
The new system, known as eMAR, is being developed at a joint clinical research center in West Valley, Utah. The companies will utilize clinical information technology that incorporates
The toll-like receptor 4 (TLR4) agonist, CRX-675, was given to participants intranasally prior to stimulation with ragweed allergen. Although the primary objective of this clinical trial was to
The placebo-controlled trial examined the safety and tolerability of three doses of VP025, Vasogen’s drug candidate, in 24 healthy volunteers. Multiple administrations of either low, mid, or high